


MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

Date: February 8, 2000
To: Dockets Management Branch (HFA-305)
From: Melissa Lamb
Office of Generic Drugs
Subject: Blend Uniformity Analysis

This memorandum forwards overheads of a presentation to the Dockets Management Branch for inclusion in Docket 90S-0308. The following is information on the presentation for the Docket records:

Title of Presentation: Blend Uniformity Analysis
Presented for: 1999 Fall Technical Workshop
Date Presented: 10/19/99
Presented by: Dave Gill, Ph.D.
Number of Pages: 8



Attachment

3872 '00 FEB 11 A9:25

90S-0308

M659

Fall Technical Workshop

October 19, 1999

BLEND UNIFORMITY ANALYSIS

Dave Gill, Ph.D.

Team Leader

Division of Chemistry I

Office of Generic Drugs

Blend Uniformity Analysis (Background)

- Generic applicants started filing in-process controls
- Applicants complained about review chemists' recommendations
- Outside auditor assessment
- DPTC chair trained OGD review chemists
- DPTC chair drafted guidance for generic industry
- Draft guidance was published in August

Contents

ANDAs: Blend Uniformity Analysis

- Introduction
- Scope
- Sampling size and procedures
- Acceptance criteria and analytical procedures
- Attachments A and B
- Glossary

Blend Uniformity Analysis Draft Guidance (Introduction)

- Major application to solid oral dosage forms
- Recommendations are for abbreviated new drug applications
- Supplemental applications for formulation and process changes
- Cites ANDA and CGMP regulations for in-process controls
- Seeking support of product quality research institute
- Certain dosage forms, strengths, and w/w percentage
- Sample size, procedures, and acceptance criteria

Blend Uniformity Analysis Draft Guidance (Scope)

- Bioequivalence, test, and production batches
- The USP content uniformity test requirements
- Complex dosage forms and complex processes
- Deletion of BUA through supplemental application?
- Necessary under CGMP?

BUA Draft Guidance (Sampling Size and Procedures)

- NMT 3x the weight of dosage unit
- NMT 10x when justified for sampling bias
- Sample from each drum or blender
- Six to ten samples from designated locations
- No composite sampling from various sites
- Equivalent to one dosage unit weight analyzed

BUA Draft Guidance (Acceptance Criteria and Analytical Procedures)

- Describe analytical procedures in section XII
- Report individual test results, mean, and RSD
- Mean of individual test results should be 90-110%
- RSD be not more than 5.0%
- Two-Tier acceptance criteria not recommended
- Tighter than USP's content uniformity release test

Drug Product Technical Committee

- Dave Gill, Chair (OGD)
- Joseph Sieczkowski, Vice Chair (ONDC)
- Luann Pallas (OC)
- Upinder Atwal (OGD)
- Martha Heimann (ONDC)
- Raj Uppoor (ONDC)
- Amit Mitra (ONDC)
- Andrea High (OGD)
- Ajaz Hussain (OTR)